drugset / Trial / NCT04762875

MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

NCT04762875

Phase 2 Terminated 7 enrolled Ensoma National Marrow Donor Program · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study tests a new medicine for mobilizing stem cells so they can be collected and used for allogeneic stem cell transplant for treatment of hematological malignancies. MGTA-145, the new medicine, will be given with plerixafor.

Timeline

Start
2021-06-16
Primary completion
2021-09-14
Completion
2022-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject MGTA-145 Protein / enzyme biologic Intravenous
Subject Plerixafor Small molecule 240 ug/kg Subcutaneous